These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18845495)

  • 1. [Tumor vasculature as a therapeutic target in non-small cell lung cancer].
    Döme B; Magyar M
    Magy Onkol; 2008 Sep; 52(3):247-59. PubMed ID: 18845495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Horn L; Sandler AB
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
    J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In pursuit of new anti-angiogenic therapies for cancer treatment.
    Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
    Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
    Török S; Döme B
    Magy Onkol; 2012 Mar; 56(1):3-15. PubMed ID: 22403757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lung cancer].
    Fischer B; Buhl R
    Med Klin (Munich); 2008 May; 103(5):311-20. PubMed ID: 18484217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
    Török S; Cserepes T M; Rényi-Vámos F; Döme B
    Magy Onkol; 2012 Sep; 56(3):199-208. PubMed ID: 23008829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib in non-small cell lung cancer.
    Zhang J; Gold KA; Kim E
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1417-26. PubMed ID: 22725255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis Inhibitors in NSCLC.
    Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel molecular targeted therapies for refractory thyroid cancer.
    Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
    Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies in the treatment of advanced/metastatic NSCLC.
    Pallis AG; Serfass L; Dziadziusko R; van Meerbeeck JP; Fennell D; Lacombe D; Welch J; Gridelli C
    Eur J Cancer; 2009 Sep; 45(14):2473-87. PubMed ID: 19596191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
    Lee CB; Socinski MA
    Rev Recent Clin Trials; 2007 May; 2(2):117-20. PubMed ID: 18473996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
    Rini BI
    Curr Oncol Rep; 2006 Mar; 8(2):85-9. PubMed ID: 16507216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors and the thyroid.
    Sherman SI
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):713-22. PubMed ID: 19942148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S23-30. PubMed ID: 17239287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting angiogenesis in esophagogastric adenocarcinoma.
    Okines AF; Reynolds AR; Cunningham D
    Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.